Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

NCT07105709 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07105709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07105709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Recruiting
Start date
August 14, 2025
Completion date
December 8, 2028
Enrollment
220 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease